Biomaterial Database

Bone mineral loss in HIV-positive patients receiving antiretroviral therapy. 2000

J E Weiel, and J M Lenhard

UI	MeSH Term	Description	Entries
D010024	Osteoporosis	Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D011480	Protease Inhibitors	Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).	Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658	HIV Infections	Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380	Anti-HIV Agents	Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.	AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

J E Weiel, and J M Lenhard

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

March 2000, AIDS (London, England),

J E Weiel, and J M Lenhard

Accelerated bone mineral loss in HIV-positive patients.

April 2000, The AIDS reader,

J E Weiel, and J M Lenhard

Response to 'Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy' by Drs Weil and Lenhard.

October 2000, AIDS (London, England),

J E Weiel, and J M Lenhard

[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].

March 2004, Anales de pediatria (Barcelona, Spain : 2003),

J E Weiel, and J M Lenhard

Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy.

May 2006, The American journal of medicine,

J E Weiel, and J M Lenhard

Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.

March 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...,

J E Weiel, and J M Lenhard

Plasma microRNA expression levels in HIV-1-positive patients receiving antiretroviral therapy.

May 2020, Bioscience reports,

J E Weiel, and J M Lenhard

Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy.

February 2007, The American journal of clinical nutrition,

J E Weiel, and J M Lenhard

Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy.

August 2021, International journal of clinical practice,

J E Weiel, and J M Lenhard

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.

September 2001, AIDS (London, England),